Sidney Kimmel Comprehensive Cancer Center

Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial

Response assessment criteria in patients with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) have been updated in the 2023 International Working Group (IWG) criteria. However, validation of these criteria has been limited to date. We analyzed overall survival (OS) by be...

HMGA1 and HMGA2: epigenetic regulators in myeloproliferative neoplasms and novel platelet transcriptomic biomarkers of myelofibrosis

We read with great interest two recent studies by Handa et al. [ 1 ] and Bartalucci et al. [ 2 ] reporting novel chromosomal deletions within the 3’ untranslated region (UTR) of HMGA2 (Δ3’ HMGA2 ) in myeloproliferative neoplasms (MPNs). Both teams identified submicroscopic deleti...

Cryo-EM structures of autoinhibited and RNA-activated ZNFX1 helicase

Abstract ZNFX1 is an RNA helicase that plays a critical role in host defense against viral infections. Recent studies further revealed that ZNFX1 harbors an unexpected RNA-ubiquitinating E3 ligase activity, raising fundamental questions about how RNA-binding activates this multif...

Randomized phase II trial of liposomal cytarabine and daunorubicin with or without pomalidomide in newly diagnosed acute myeloid leukemia myelodysplasia-related

Not available.

Targeting RAS for Pancreatic Cancer Interception

Multiple strategies to target RAS are now available to treat pancreatic cancer. As pancreatic precancers also have KRAS mutations, these tools hold great promise for cancer interception.

New Annular, Indurated Plaques During Mogamulizumab Therapy in Cutaneous T‐Cell Lymphoma: A Clinicopathologic Pitfall

ABSTRACT New annular, indurated plaques arising during mogamulizumab therapy for cutaneous T‐cell lymphoma (CTCL) present a diagnostic challenge, as they may raise concern for treatment‐related eruption or disease progression. We report two patients with darker skin types who dev...

Perceptions of and Barriers to Colorectal Cancer Screening Uptake in Underserved Baltimore and Eastern Shore Populations

Colorectal cancer (CRC) remains a leading cause of preventable cancer mortality, with persistent screening disparities in underserved communities. This qualitative study aimed to identify community-specific barriers to CRC screening among two distinct Maryland populations to info...

Hyper‐Intense Tumor Peripheral Accumulation of Antibody‐Conjugated Iron Oxide Nanoparticles can Enable Breast Cancer Detection by Magnetic Particle Imaging

ABSTRACT Targeting nanoparticles to cancer cells in vivo remains a challenge for cancer imaging. We assessed nanoparticle distribution after injecting iron oxide nanoparticles conjugated with either a monoclonal anti‐HER2 (human epidermal growth factor 2), or a non‐specific IgG a...

Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

Baseline IPSS-M risk, response to hypomethylating agent (HMA) therapy, and receipt of allogeneic stem cell transplant (allo-HCT) have all been individually shown to impact overall survival (OS) in patients with myelodysplastic syndromes (MDS). However, the prognostic impact of re...

Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1-mediated cell-intrinsic resistance

SUMMARY While nucleoside DNA methyltransferase inhibitors (DNMTi) such as decitabine and azacitidine are effective in treating myelodysplatic syndrome (MDS)/leukemia, they have had limited utility for the majority of other cancers. Through a chemical library screen, we identified...

SPINK1-COL18A1 crosstalk shapes epigenome and drives cancer stemness in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a devastating cancer with an increasing incidence and extremely dismal prognosis. Discovery and mechanistic understanding of the genetic and epigenetic drivers of PDAC is therefore of critical importance. Here, we uncover serine protease...

Practical management of BRAF inhibitors in glioma: toxicity and resistance

BRAF inhibitors have advanced treatment for patients with BRAF-altered high and low-grade glioma (HGG and LGG, respectively). Clinically-available therapies are effective but require selection by mutation type and careful, proactive toxicity management to maximize patient quality...

Protocol for optogenetic stimulation of cells under physical confinement

Optogenetic approaches enable spatiotemporal control of signaling proteins, yet their integration with microfluidic assays to study confined cell migration remains challenging. Herein, we present a protocol for the optogenetic activation of PI3K/Akt signaling in confined cells. W...